Regular Article

Cyclobenzaprine drug assay and Cyclobenzaprine-excipient interaction study by chromatography, thermal and spectral analysis

Rajasekhar Tulasi Baru*, Prasanth Bitla
1Granada Pharma Ltd., Granada, PO BOX 11797, Riyadh 3939, Saudi Arabia
2University of Hyderabad, Prof CR Rao Rd, CUC, Gachibowli, Hyderabad, Telangana 500046, India

*Correspondence Email: barurajasekhar@gmail.com

Received 04 September 2017; Revised 10 April 2018; Accepted 24 May 2018; Published 30 July 2018
Editor: Mohammad Ashrafuzzaman

Abstract
The present study was carried out to investigate the compatibility of Cyclobenzaprine hydrochloride, a muscle relaxant and antidepressant with different pharmaceutical excipients. The study involved storing drug-excipient blends (200 mg) with 20% added moisture in closed glass vials at 100°C for 24 hours. A LC method was developed and validated for determination of cyclobenzaprine. The mobile phase consists of potassium dihydrogen phosphate buffer (20 mM, pH 3.0): methanol with flow rate 1.2 mL/min and UV detection at 280 nm. A good linearity was obtained with concentration ranging from 5-50 µg/mL. The HPLC study showed, drug interacts with some commonly used pharmaceutical excipients. The results were fairly good in agreement with the cyclobenzaprine hydrochloride-excipient interaction analysis, obtained from DSC, FT-IR, UV-DRS. The HPLC method was validated as per ICH guidelines and applied for quality control of bulk and formulation of cyclobenzaprine hydrochloride.

Keywords: Cyclobenzaprine, Excipients, degradation/interaction products, HPLC, DSC, UVDRS
Introduction

Cyclobenzaprine hydrochloride (CBZ) is widely used as muscle relaxant and antidepressant. Chemically, it is 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride. In drug development process, Drug-Excipient interaction study plays important role. The ultimate goal of adding excipients is delivery of drug in pure and safe form to the target. Drug-excipient compatibility testing at an early stage helps in the selection of excipients that increase the probability of developing a stable dosage form (1). Ideally excipients should be chemically inert but they may alter absorption, distribution, metabolism, and excretion of drug. During preparation and storage of drug products, new impurities may be generated. The basic reason is that it may come from interaction between drug and excipient.

HCl

Cyclobenzaprine hydrochloride

However these excipients can initiate, propagate and participate in chemical and physical interaction with active part of the formulation which result into interaction that affect the quality or shelf life of the drug product. This chemical interaction may lead to degradation of active ingredient of the formulation thus reduction in efficient therapeutic response. Physical interaction can affect rate of dissolution, uniformity of dose, solubility, disintegration, bioavailability of parent drug. Excipients may have functional group that interacts with Active Pharmaceutical Ingredient (API) which results into formation of degradation product. The available literature shows that this study can be performed with the help of X-ray diffraction spectroscopy, DSC, HPLC, FT-IR spectroscopy (2-5).

Experimental

Instruments and Equipments

The various sophisticated analytical instruments were used for the study. An isocratic HPLC (Shimadzu Prominence, Japan) with single LC-20 AD pump, SPD - 20A UV visible detector, Phenomenex Luna C18 column (250 mm x 4.6 mm, 5 µm) and Rheodyne injector with a 20 µL loop was used for the injection of the sample. Differential Scanning Calorimeter (Universal V4.5A, TA Instruments) was used for thermal study. FTIR spectrophotometer (Spectrum RXI, Perkin Elmer, USA), UV-DRS (V-650, Jasco Corporation, Japan) and HPLC system equipped with LC solution (Database Version 1.24.SP1, Milford, USA) were used for whole study. All pH measurements were done using pH-meter (pH Tutor, Eutech Industries, Malaysia) and weighing was done using Sartorius balance (CPA225D, Germany). Digital Sonicator (Power sonic 405, Hwashin Technology Corporation, Korea) used for sonication purpose. Digital hot air oven (Bio techniques, Mumbai, India) was used for solid state stress study.

Reagents and Chemicals

Cyclobenzaprine hydrochloride was received as gift sample from Gelmark pharma limited. Pharmaceutical excipients like dibasic calcium phosphate (DCP), lactose anhydrous, corn starch, magnesium stearate (MgStearate), silicon dioxide (SiO2), titanium dioxide (TiO2), talc, sodium carboxymethyl cellulose (NaCMC), hydroxylpropyl methylcellulose (HPMC) were obtained as gift sample from Gelmark pharma limited Hyderabad. HPLC grade methanol (SD Fine chemicals), HPLC grade water (Millipore, USA), potassium dihydrogen phosphate -buffer and ortho-phosphoric acid were obtained from SD Fine chemicals, Test samples, cyclobenzaprine hydrochloride 5 mg per tablet, purchased from local market (Flexabenz, Macleods pharmaceutical Ltd.) was used for the study.

Methods

Chromatographic condition

Phenomenex C18 (250x4.6 mm, 5 µm) column was used for the HPLC study. The mobile phase containing methanol:potassium dihydrogen phosphate buffer (20 mM, pH 3.0) in proportion of 65:35 (v/v) was found an precise and cheaper LC method for present study. Orthophosphoric acid was used for pH adjustment for an aqueous medium. The mobile phase was filtered through 0.45 µm Whatman Cellulose Acetate membrane filter paper and then ultrasonicated for 30 min. The flow rate was set to 1.2 mL/min. 289 nm was selected as wavelength maxima. Column temperature was kept at ambient condition throughout the analysis. Injection volume was 20 µL.

Validation of LC method and assay of drug tablet formulation

The method was validated for linearity, range, precision (inter-day, intra-day and intermediate
Degradation studies
Drug-excipient interaction study involved preparation of blends of drugs substances with different pharmaceutical excipients, which were mixed with 20% added water and stored in closed glass vials at 100°C for 24 hours. Samples were analysed for chemical and physical (colour, appearance, etc.) stability after 24 hour of storage. These specific study parameters were set on the basis of trials and errors. For test samples, accurately weighed amount of drug-substances were placed in 5 mL glass vials. Each vial was labelled with the amount of drugs to determine mass balance during chemical analysis and weighed amounts of excipients were then added to the vials. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance and excipients in a blend was taken in 1:1 ratio, the powder in each vial was mixed with a glass capillary (both the ends of which were heat sealed). Then 20% water (40 µL per 200 mg powder blend) was added using micro syringe. The blend was further mixed with same glass capillary and to prevent any loss of material, capillary was broken and left inside the vial. Each vial was sealed tightly with a teflon-lined screw cap and stored at 100°C for 24 hours. The same way, control samples were prepared and kept at ambient temperature, same procedure as per test sample was followed without addition of drug substance for Blank samples.

HPLC studies
The samples were observed visually for any physical changes and also analyzed by a newly developed and validated HPLC method to determine chemical changes. 3 mL of mobile phase was added into each vial. The mixture was vortexed and transferred to 100 mL volumetric flask. Each vial was rinsed with solvent (mobile phase) thrice and volume was made up to mark. The resulting samples were centrifuged and supernatant was filtered through 0.45µm cellulose acetate membrane filters. After final dilution, samples were analysed using HPLC and drug content determined using calibration curve preparation within range.

DSC studies
A differential scanning calorimeter was used for thermal analysis of drug and mixtures of drug and excipients. HPLC showed positive results for excipients like Mg.stearate, NaCMC so only they were analysed by DSC for conformation study. Samples were weighed directly in the pierced DSC aluminium pan and scanned in the temperature range of 25-250°C with 10°C/min heating rate under 25 mL/min nitrogen flow rate. Thermograms obtained under given condition were observed for interaction.

FTIR spectroscopy studies
FTIR spectra of drug and drug-excipient blends were recorded on an FTIR spectrophotometer in the range of 4000-400 cm⁻¹ using potassium bromide discs.

UV-DRS studies
UV-DRS spectra drug and drug-excipient blends were obtained on an UV spectrophotometer in the range of 210-870 nm (see supplementary data).

Results and discussion
Drug-excipient compatibility study
HPLC was used for quantitative study among all techniques, remaining were used for qualitative study. Figure 1 shows that stressed sample retention time and area have been changed as compare to control sample. It means drug has interacted with MgStearate. The same way, Figure 2 is showing changed retention time and drug peak area for stressed sample. So in the case of NaCMC also drug has degraded. %Recovery of cyclobenzaprine hydrochloride with excipients after stress condition is listed in table I. The Table I clearly indicates that cyclobenzaprine hydrochloride is not compatible with MgStearate and NaCMC (%Recovery beyond 100±5.0) and remaining excipients showed a least interaction with CBZ. For further confirmation of interaction, study was supported by DSC, FT-IR and UV-DRS.

<table>
<thead>
<tr>
<th>Sample (Blank)</th>
<th>CBZ</th>
<th>CBZ + MgStearate</th>
<th>CBZ + NaCMC</th>
<th>CBZ + Tack</th>
<th>CBZ + Excpt</th>
<th>CBZ + Excpt</th>
<th>CBZ + Excpt</th>
<th>CBZ + Excpt</th>
<th>CBZ + Excpt</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recovery (%)</td>
<td>100</td>
<td>78.77</td>
<td>80.68</td>
<td>90.71</td>
<td>97.28</td>
<td>101.10</td>
<td>99.37</td>
<td>98.96</td>
<td>99.51</td>
</tr>
</tbody>
</table>
Figure 1. CBZ-MgStearate interaction by HPLC.

Figure 2. CBZ-NaCMC interaction by HPLC.

Figure 3. DSC thermogram of CBZ control sample.

Figure 4. DSC thermogram of CBZ stressed sample.

Figure 5. DSC thermogram of CBZ-MgStearate control sample.

Figure 6. DSC thermogram of CBZ-MgStearate stressed sample.
Selected drug-excipient mixtures were scanned by DSC for further confirmation as shown in Figures 3-8. The thermal behaviour of control and stressed samples of pure drug and mixtures were checked and compared. Peak transition temperature \( T_{\text{peak}} \) and heat of fusion or enthalpy \( \Delta H_f \) of cyclobenzaprine hydrochloride alone and in MgStearate and NaCMC are summarized in Table I. The DSC trace of cyclobenzaprine hydrochloride showed a sharp endothermic peak at 218.62°C. In majority of the cases, melting endotherm of drug was well preserved with slight changes in terms of broadening of peak transition temperature. The heat of fusion was also decreased (from 121.2 J/g to 54.51 J/g) which indicated an interaction. The individual endotherm parameters are summarised in Table II.

The same type of changes observed with the stressed CBZ-NaCMC (Figure 8) that showed broadening of endotherm and shifting of peak transition temperature (from 219.34°C to 205.98°C) of drug endotherm. The heat of fusion was also very much decreased (from 121.2 J/g to 54.51 J/g) which indicated an interaction.
In the present study, FTIR was used for comparison of its potency towards interaction study (Figures 9 and 10). IR spectra of stressed pure drug, excipient and stressed drug-excipient mixture were recorded from 4000-400 cm\(^{-1}\). The IR spectra of stressed CBZ is shown in Figure 9 and following main characteristic bands were observed: 2440 (C=C\(-\text{str}\)), 1476 (-CH\(_3\), bend) and 1436 cm\(^{-1}\) (-CH\(_2\), bend). Stressed CBZ-MgStearate (Figure 9) shown nearly same absorbance bands as obtained in pure drug IR spectra, the only difference was shifting and broadening of band at 1560 cm\(^{-1}\) (1460 cm\(^{-1}\) in pure drug). The same case was observed for control CBZ-MgStearate (Figure 9) that shows interaction was also took place at ambient temperature.

The scan of IR spectra of stressed CBZ-NaCMC was observed for following absorbance bands as shown in Figure 10. 2431 cm\(^{-1}\) (C=C\(-\text{str}\)) and 1475 cm\(^{-1}\) (-CH\(_3\), bend). The interaction between CBZ-NaCMC could be proved by overlaying mixture samples. The absorbance band at 2431 cm\(^{-1}\) in stressed mixture sample was observed broad as compare to control mixture sample (Figure 10). Remaining excipients were not showing any marked difference between pure drug and/or mixture samples under stressed condition.

UV-DRS is not widely used analytical technique for drug-excipient interaction study but it was used to solely compare its proficiency with currently available techniques in this area. The scan was achieved from 870 to 210 nm for UV-DRS spectra. Control and stressed samples of all the excipient-drug mixture were successfully scanned but no one has shown significant interaction with CBZ except NaCMC (Figure 11).

Validation and assay result
Validation of HPLC method was performed covering most of the validation parameters (Tables III), as per the ICH guideline Q2(R1). Linearity (R\(^2\)) and %RSD were obtained 0.9998 and less than 1.00\% respectively. Robustness (Table IV) and system suitability parameters were performed showing %RSD less than 2.00 that means the present LC method is robust (Table V, VI). The assay was performed for marketed formulation (tablet) for three different concentrations. %Recovery was found within the range (Table VI).
Conclusion

The results confirmed that cyclobenzaprine hydrochloride is not compatible with MgStearate and NaCMC out of all selected pharmaceutical excipients. The study was also aimed to compare HPLC study results with DSC, FTIR and UV-DRS results for drug-excipient interaction study. In the present study, results of HPLC with other techniques were successfully employed to assess the compatibility of cyclobenzaprine hydrochloride with the excipients used in the tablet formulation. No concrete evidence of interaction was observed between cyclobenzaprine hydrochloride and majority of the excipients used in the tablet formulation of the same drug. The comparison indicated that only HPLC results cannot be relied alone. Whenever possible, other techniques such as DSC, FTIR and UV-DRS and quantitative analysis after storage under stressed conditions should be taken in conjunction with HPLC results to reach any definite conclusion.

Conflict of interest

The authors declare that they have no competing interest.

Reference


interaction; *International Journal of Pharmacuetics*, 2003; 252: 135-140


Supplementary Materials

New Drug Excipients

---

**Spectrum Pathname**
CBP HCl pure (normal) 19102010.001

**Description**
- CBP HCl+Mg.St. stressed sample
- CBP HCl+Mg.St. Control.19-10-10.002

**Date Created**
- 19102010.001
- 19102010.002

**Instrument Model**

**Time:** 2:33:07 PM

---

Baru and Bitla 2018. Biomedical Sciences Today 3:e17
Spectrum Name: CBP HCl+Na CMC-Stressed sample
Spectrum Pathname: 20102010.002
Description: CBP HCl+Na CMC-Control-20102010.002
Instrument Model:
Analyst: Pure Drug (Stressed) 19102010.002
Date Created: NaCMC.002
Baru and Bitla 2018. Biomedical Sciences Today 3:e17
UV DRS

**Mg st**

- Sample types: control, drug, extractant

**Na CMC**

- Sample types: control, drug

---

Baru and Bitla 2018. Biomedical Sciences Today 3:e17